1. Home
  2. RSG vs REGN Comparison

RSG vs REGN Comparison

Compare RSG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Services Inc.

RSG

Republic Services Inc.

HOLD

Current Price

$219.50

Market Cap

67.5B

Sector

Utilities

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$779.67

Market Cap

79.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSG
REGN
Founded
1996
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5B
79.4B
IPO Year
1998
1995

Fundamental Metrics

Financial Performance
Metric
RSG
REGN
Price
$219.50
$779.67
Analyst Decision
Buy
Buy
Analyst Count
19
23
Target Price
$248.32
$812.57
AVG Volume (30 Days)
1.4M
732.6K
Earning Date
05-20-2026
04-16-2026
Dividend Yield
1.13%
0.48%
EPS Growth
5.55
8.19
EPS
6.85
41.48
Revenue
$19,027,000,000.00
$5,872,227,000.00
Revenue This Year
$5.49
$11.69
Revenue Next Year
$5.13
$10.12
P/E Ratio
$32.04
$18.80
Revenue Growth
3.31
20.82
52 Week Low
$201.42
$476.49
52 Week High
$258.75
$821.11

Technical Indicators

Market Signals
Indicator
RSG
REGN
Relative Strength Index (RSI) 53.24 53.11
Support Level $209.48 $783.62
Resistance Level $224.61 $815.00
Average True Range (ATR) 5.01 22.83
MACD -0.15 1.25
Stochastic Oscillator 57.44 58.08

Price Performance

Historical Comparison
RSG
REGN

About RSG Republic Services Inc.

Republic Services Group is the second-largest waste management company by revenue and provides integrated waste management services to residential, commercial, and industrial customers. With 208 active landfills, 248 transfer stations, and 75 recycling centers, Republic Services has reached $16 billion in annual revenue, focusing on recycling and environmental solutions. The company reports in three segments based on the Western United States (Group 1), Eastern United States (Group 2), and Environmental Solutions across North America (Group 3). Eighty-nine percent of total revenue comes from recycling and waste, with the remaining 11% from Environmental Solutions.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: